everyone We to the and you, joining call you time the for taking afternoon. to this listening. you Thank thank Paula, appreciate
As are aware to November name name. our of most of changed ThermoGenesis. from Therapeutics brand original its you Xst, company Cesca we as
For cell more technologies and ThermoGenesis than the well-respected been blood in cord cell industry. separation stem and cryostorage for brand three global recognized a decades, automated has
the them has helps and to and cell processing deliver with blood clinicians company outcomes researchers, and cord series biomanufacturing and banking which processing a better systems, various of The developed commercialized technologies organizations global regenerative cell in applications providing highly devices medicine. in efficient
the therapy cell cell-based leverage refresh focus unmet provider including become chimeric in to cell the renewed field critical and gene processing we services arena, emerging the field. CAR-T needs receptor In interest for The T-cells automated and last company's or the tools the growing fast and recent in change cell to leading years, our antigen cell. expertise name processing the strategic further in two the address immunotherapy
history a want ThermoGenesis of XXXX I the Before company. strategy corporate and achievements, founded recent in provide I provide to was an originally update brief first as the device on our medical Company.
including a and Company automated These the long cord as as stem blood for XXs, worldwide, outside used separation Anderson, CBR blood NYBC, of York world's series or the Cord successfully Corporation, public Clinic, private the Registry cell being the largest U.S. and the New Blood Cord banks the of leading institutes private of have and leading the of – the bank the Blood blood MD technologies a During by technologies Center, the Blood cord developed the well largest bank private at cell blood Cleveland list U.S. stem Global cord cell industry. in and Duke, cryostorage cord
the over has only the not few in encountered also the years financial the difficulties. company. I'm largest that past With investor CEO severe I'm the ThermoGenesis, of said, Company
XXXX Group invested to bankruptcy. subsequently early In when the company. company $XX million credit on operations revived through of extent the a founded which company verge was another of I I million BoyaLife further line XX and support the the
and XXXX I positive the the continuous CEO around. we of the company flow The later. one then, turnaround CEO year took strategy a Since the the set as in the number of became As yet interim operation. part from position November to turn to series full-time achieve goal goals of about have cash
the have to we achieve to last to us set goal. years, significant that, this made in say glad I'm changes which few the company
operational aggressive costs. increase One was measures of in taken to reduce and to our revenue have We the areas second operations. two was
become undertaken flow in copy order cash of corporate find presentation we positive. can thermogenesis.com, www. website; on a series our of measures latest our which the to You outlines have
or proprietary made CAR immunotherapy into XXXX, Inc., device a BACS sorting field which SynGen Sacramento technology based developed technology. emerging July in a a technology This includes; transformative footprint examples T company our for strategic ThermoGenesis expanded medical and activated of few the the A company acquisition was cell buoyancy
intellectual own newly the X-Lab, in technology, the including our the the X-Wash, X-Series X-Mini with development. products new combination new and property platform acquired we and In CAR-TXpress BACS and launched in the X-BACS XXXX
unmet These costs most technology platforms selling of reduce and including help is therapies gene of products which address critical drug needs. significant The to manufacturing the for CAR-T.
our improve we and efficiency late renegotiate manufacturing our by XXXX, reduction series effectively we product In Also of XXXX, cost in a XX%. overhead contract operational costs. implemented aggressive reduce measures reducing our costs to
the therapy manufacturing Coming for point-of-care to we clinical settings additional launch and and cell products continued XXXX, biobanking, tools and gene fields. new for to large-scale processing cell services clinical and
So the and me a asset include. quarter highlight with our We for our five-year global achievements to clinical We distributor medicine recent global agreement on and tools service highlights that distribution products. into third let QX regions processing a the focused X-Series divested our – cell stay entered business.
a And of venture provide to order critical compliant banking joint a immune third, accessibilities for using site address immune recently agreement patient's most we with platform, USA services CAR-T our definitive GNP called immunotherapy. needs form unmet other Biotech CAR-TXpress HealthBanks future to to in cell which announced and
goal. second objectives our positive continued was to very and significant to third achieve stated progresses of I'm year-end. for cash to that pleased operations by towards report XXXX over make quarters, One flow this key from the we
of past the increase the financial over performance measures. steadily quarters. company With continued several improved has and revenue The cost reduction
the of seven Over quarters XXXX. past since beginning the
As have noted over a a company the approximate operational were the to measure Using best the cash-based second key the XXXX. performance, in for row third metrics note cash release EBITDA, of to flow. that financial uses I'm delighted press adjusted $X.X for we achieved EBITDA XX% as quarter positive in the to adjusted increase the determining quarter the million, quarter third revenue
second in adjusted company quarter adjusted of of $XXX,XXX a With that of reached XXXX increase. and XXXX the representing third the fixed positive quarter rate, positive EBITDA $XX,XXX EBITDA the in of a XXX%
in necessary. funds to its resources adjusted positive much wisely that deems EBIDA areas A key utilize more company in allow it the
$X.X increase of an quarter from in the hand million We third on second the to in also quarter. XXXX million in $X.X cash saw
our distribution our include Jeff And over distributor, we than financial the $X CEO. call. as is stronger the position took go cash-on-hand Clearly financials And the into analysis when yet $X.X global October in from much to would the million formally Xst I increased received later a will million. of company in be fee detailed global this
market the marketed three of products. -- Currently company cell processing platforms
the cell first platform technology. is CAR-TXpress on The buoyancy-activated based sorting
cell kits. BACS for includes the And washing rapid The for using system high-efficiency sorting microbubbles. and lipids The X-Lab isolation. reformulation. platform The patent cell system a the X-Wash is technology CAR-TXpress technology protected X-Mini, reagent cell
for cellular manufacturing X-BACS therapies. CAR-T system Currently X-Series of products. are all Together these in the large-scale development called is
AXP/BioArchive cryostorage the allows for platform and automated blood samples. Second processing for and cord clinical clinical which biobanking, of
PXP point-of-care as point-of-care clinics. autologous centers automated applications, the at at locations peripheral Third, surgical bone marrow or cells for which for or that processing such stem allows blood the derive platform of the
In our the Marcus system performance Duke cells Center reported Medicine September, medical for Carolina. two University centers. University cure we School validation Cancer for from X-Series of at The of of products cellular and of Center at North Comprehensive well-recognized academic Lineberger
a for third-party the announced products, milestone agreement distributor prestigious newest medical we to pleased company. are very X-Series a received In also We these our with products centers. highly for September, X-Series a global such validations our global significant from of major have distribution commercialization
for with worldwide to distributor this our renewable first will marketing customers responsible the existing five-year for for exception our X-Series products including two be Under the years. agreement, China
is our This As million support agreement future will receive technologies the from ThermoGenesis profit. to expand $X awareness and and of distributor. increase anticipated marketing fee CAR-TXpress agreement achieve a cutting-edge will the part of received that the in vastly expected market, the cells we us distribution research upfront continue the help revenue sustained to to
and and will us also marketing focus great developing the products X-Series of Celgene sales for the point-of-care allow tools to the additional therapy the seeing maintained and services on market. Also
divested recently we clinical our least, not but programs. Last
team will positioning As of XXX% a its the company services. market cell the effort at superior the products with and addressing the the of towards it's gene manufacturing of and critical this result, unmet therapy and needs forefront devote effort ThermoGenesis's
patient to is to cell benefits future gene of need therapy ensure increased of it through of mission and and accessibility. The reduction manufacturing costs ThermoGenesis everyone
have to be research robust. we and Immunotherapy strategic clinical the growing area, research the would continues of Due to direction. fastest why remains to activity important result one I a like immunotherapies focus our as new this taken cancer for reiterate the cell-based,
According the has in alone ongoing clinical clinicaltrials.gov trials surpassed a pending to of worldwide. therapy number cell and the space growth XXX CAR-T
which challenges manufacturing there and remain the including costs. However are these use expanding barrier life-saving therapies. of of Both significant the most to well-known high promising manufacturing efficiencies low
of dose immunotherapy unmet published fail This promising T or recently technology. being than XX% fail to that highlights addition, needs, to more the some have cases that accessibility low another in shown results significant either the low when in cells the patients to a yet patients of receive of sufficient in trial In needed. clinical CAR
ThermoGenesis the developed significant will research, by company commercialized XXXX and of the and founded novel has these in in be devices cell used needs. organizations efficient unmet systems Since high clinicians fighting forefront and processing biomanufacturing worldwide. its
expand of launch significantly be current procedures. associated area, to potential rate reduced processing standard platform buoyancy two-thirds we the activated therapy cell our CAR-T sorting cellular platform successful of will cell costs by by further serious a CAR-TXpress the With able patents with and the cell protected in automated manufacturing processing from
one into of a seen, definitive Life In leading or stem the network October form cell as USA, agreement most with Sciences to venture have a of Biotech entered bank HealthBanks ImmuneCyte. called ImmuneCyte you joint we
of processing manufacturing use allow contract immune the Doing for so, we'll immediate the cell in CAR-TXpress platform and proprietary for cell cell-based banking services. ThermoGenesis commercialization
cells, their exciting in paramount to first as to CAR-T is us being bank use immune endeavor will immune other This and bank among cell gene clients for year future U.S. is and opportunity provide own the cell therapies. be new for for the the which ImmuneCyte
unmet rationale providing to Let services. such the and the services accessibility bit enhance help new cell-based banking the patient immunotherapies. And the needs me of provide critical cell and other will immune therapies how for a CAR-T context for
ago, several CAR-T although as to therapy. XX% to cells for not As many sufficient to of to on highly cancer be that the eligibility recent enroll clinical as have CAR-T of trials patients manufacturers the studies eligible effective the get I XX% alluded shown a or may patient low in moment
and radiation the data severely includes cell that chemotherapy decay therapies. immune and during this fact radiation body's and was age also system compromised driving Factors
relevant to own healthier T-cells. enter interfere source, in especially for also joint resource future of these advanced venture cells cellular cases by and and healthy be preserves cells with cancer contaminate younger, only uncontaminated Additionally blood if many to leukemia, people use production body's not patient ImmuneCyte allowing to stream as used -- immunotherapy. to issues immune a to these address and cells get their proactivity directly he natural with and The of but the cancer aims
in Given can is platform that by launch ImmuneCyte to as immunotherapies. massive, the patients ImmuneCyte banking to fourth for of official a The at compared will to to key mission planning more these processing efficiency be future increase benefit advance quarter so XX-folds of cost. traditional XXXX. of that the our promising ImmuneCyte CAR-TXpress will very an access to technology cell have able up ImmuneCyte is offer reasonable
It of to In light Therapeutics ticker this goes ThermoGenesis changes name without its that KOOL from excited Inc. made Inc. we to phase Trading have saying next NASDAQ as Cesca enter and company ThermoGenesis. the from Board approved we are THMO. all company strategy our the these to Holding we change for
leading that is and is markets. objectives critical in tools our gene provider to move for for therapy solution a wholly cell the services which strategic cell was line This a processing stated become and with
afford Recognizing that the our determined have change shareholder growth and planned, platform number with us originally great our of this our products and broader to and going assistant, forward. even markets potential focus we of of opportunities strategy the address
let that, quarter. Jeff financial share third me results key call with over from the to And the the to turn Jeff?
